Scarica l'app Stockscreener
82.41
1.44%
1.17
Dopo l'orario di chiusura:
81.90
-0.51
-0.62%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$81.24
Aprire:
$81.28
Volume 24 ore:
8.08M
Relative Volume:
1.11
Capitalizzazione di mercato:
$105.69B
Reddito:
$33.54B
Utile/perdita netta:
$4.66B
Rapporto P/E:
22.77
EPS:
3.62
Flusso di cassa netto:
$5.19B
1 W Prestazione:
+1.85%
1M Prestazione:
-2.59%
6M Prestazione:
-4.77%
1 anno Prestazione:
+1.13%
Intervallo 1D:
$81.25
$82.42
Intervallo di 1 settimana:
$79.93
$82.42
Portata 52W:
$75.96
$96.25
Medtronic Plc Stock (MDT) Company Profile
Nome
Medtronic Plc
Settore
Industria
Telefono
01135314381700
Indirizzo
BUILDING TWO PARKMORE BUSINESS PARK WEST, GALWAY
Confronta MDT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MDT
Medtronic Plc
|
82.41 | 108.21B | 33.54B | 4.66B | 5.19B | 3.62 |
|
ABT
Abbott Laboratories
|
132.85 | 231.49B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.50 | 154.81B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
382.35 | 145.13B | 23.22B | 2.86B | 3.58B | 7.40 |
|
EW
Edwards Lifesciences Corp
|
77.73 | 44.64B | 5.54B | 4.18B | 623.10M | 7.00 |
Medtronic Plc Stock (MDT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-04 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-10-10 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-08-21 | Reiterato | Oppenheimer | Perform |
| 2024-08-15 | Aggiornamento | UBS | Sell → Neutral |
| 2024-08-14 | Downgrade | Stifel | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Sell |
| 2023-07-19 | Iniziato | Robert W. Baird | Neutral |
| 2023-06-30 | Iniziato | CL King | Buy |
| 2023-05-30 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-04-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-29 | Downgrade | UBS | Buy → Sell |
| 2023-01-09 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-11-23 | Downgrade | Citigroup | Buy → Neutral |
| 2022-11-23 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-11-16 | Downgrade | Deutsche Bank | Buy → Hold |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-13 | Iniziato | Mizuho | Buy |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-08-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-07-06 | Iniziato | Wolfe Research | Underperform |
| 2022-06-01 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-05-27 | Downgrade | Needham | Buy → Hold |
| 2022-04-13 | Downgrade | Truist | Buy → Hold |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-01-10 | Downgrade | BTIG Research | Buy → Neutral |
| 2022-01-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-12-17 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-12-16 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-06-10 | Ripresa | Cowen | Outperform |
| 2021-05-25 | Iniziato | Barclays | Equal Weight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2020-12-15 | Aggiornamento | Goldman | Sell → Neutral |
| 2020-12-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-10-08 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2020-10-08 | Aggiornamento | Stifel | Hold → Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Peer Perform |
| 2020-05-14 | Downgrade | DZ Bank | Buy → Hold |
| 2020-03-30 | Downgrade | Needham | Strong Buy → Buy |
| 2020-03-25 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Sell |
| 2020-01-08 | Iniziato | SunTrust | Buy |
| 2020-01-02 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-06-05 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2019-02-04 | Reiterato | Needham | Strong Buy |
| 2019-01-03 | Iniziato | Deutsche Bank | Buy |
| 2019-01-02 | Downgrade | Citigroup | Buy → Neutral |
| 2018-12-19 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-11-28 | Iniziato | UBS | Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-08-27 | Reiterato | Argus | Buy |
Mostra tutto
Medtronic Plc Borsa (MDT) Ultime notizie
Medtronic at Bernstein Conference: Strategic Focus on Growth and Innovation By Investing.com - Investing.com UK
Transcript : Medtronic plc Presents at Bernstein 41st Annual Strategic Decisions Conference 2025, May-29-2025 11 - marketscreener.com
Medtronic To Present At Bernstein's Strategic Decisions Conference; Webcast At 11:00 AM ET - Nasdaq
Drug Device Combination Products Market Analysis Report 2025-2030: Discover the Latest Advances and Opportunities - GlobeNewswire Inc.
Medtronic (MDT) Price Target Reduced but Long-Term Buy Rating Maintained | MDT Stock News - GuruFocus
Argus Adjusts Price Target on Medtronic to $105 From $120 - marketscreener.com
Medtronic’s SWOT analysis: medical device giant faces tariffs, sees growth in RDN - Investing.com
Medtronic to spin off its diabetes businessreport - MSN
Atherectomy Devices Market Growth in Future Scope 2025-2032 | - openPR.com
Medtronic: Diabetes Spin-Off Is Near-Term Catalyst; Rating Upgrade (NYSE:MDT) - Seeking Alpha
Medtronic to separate diabetes business following recent struggles - MSN
Medtronic plc (NYSE:MDT) Q4 2025 Earnings Call Transcript - MSN
Medtronic's (NYSE:MDT) Upcoming Dividend Will Be Larger Than Last Year's - Yahoo Finance
Medtronic chairman and CEO Geoff Martha to speak at Bernstein's Strategic Decisions Conference | MDT Stock News - GuruFocus
Medtronic chairman and CEO Geoff Martha to speak at Bernstein's Strategic Decisions Conference - PR Newswire
Sector Update: Health Care - marketscreener.com
Medtronic to Split Off Diabetes Unit as Tariffs Hit Earnings - MSN
Redburn Atlantic Adjusts Price Target on Medtronic to $101 From $104 - marketscreener.com
JPMorgan Adjusts Medtronic Price Target to $87 From $95 - marketscreener.com
Jim Cramer on Medtronic (MDT): “I Like This Medical Device Powerhouse” - Insider Monkey
Blood Glucose Monitoring (BGM) Devices Market Report 2025: Hospitals Lead in Blood Glucose Monitoring Device Usage, Home Care Grows Fastest - GlobeNewswire Inc.
Endoscopy Devices Global Market Overview 2021-2030 with Forecasts 2024-2030 - GlobeNewswire Inc.
Medtronic Projects $350M Tariff Hit - Medical Device and Diagnostic industry
Medtronic to separate diabetes business into standalone company - MSN
Medtronic Announces Separation From Diabetes Business, CEO Says it’s “In a Really Good Spot” - Insider Monkey
Medtronic has new Cardiovascular, CST leaders after longtime exec departs - MassDevice
Medtronic (MDT) Plans to Spin Off Diabetes Business - GuruFocus
TD Cowen Keeps a Buy on Medtronic (MDT) After Better Growth in Q4 - Insider Monkey
Medtronic PLC stock underperforms Thursday when compared to competitors - MarketWatch
Abbott vs. Medtronic: Which Dividend-Paying MedTech Stock is Better? - Yahoo Finance
Medtronic PLC (MDT) Stock Price Down 3.66% on May 22 - GuruFocus
MDT: RBC Capital Lowers Price Target for Medtronic | MDT Stock N - GuruFocus
Medtronic (MDT) Stock Price Target Lowered by Mizuho Analyst | M - GuruFocus
Medtronic inks expanded distro deal for multi-parameter wearable vital sign monitor - MassDevice
Medtronic's Strong Q4 Performance Sets The Stage For Future Growth - Finimize
Medtronic (MDT) Price Target Lowered by Baird Analyst | MDT Stoc - GuruFocus
Medtronic (MDT) Price Target Lowered by Baird Analyst | MDT Stock News - GuruFocus
Medtronic Cardiovascular Strength Drives Fiscal Q4 Beat, RBC Says - marketscreener.com
Why Medtronic plans to spin out its diabetes business - MedTech Dive
July 3rd Options Now Available For Medtronic (MDT) - Nasdaq
Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon - MassDevice
Medtronic (MDT) Price Target Lowered by RBC Capital Amid Growth Investments | MDT Stock News - GuruFocus
Truist Adjusts Price Target on Medtronic to $92 From $90, Maintains Hold Rating - marketscreener.com
Oppenheimer Adjusts Medtronic Price Target to $92 From $94 - marketscreener.com
Medtronic (MDT) Price Target Lowered but Growth Potential Remains Strong | MDT Stock News - GuruFocus
Medtronic (MDT) Sees Price Target Reduced by Baird | MDT Stock N - GuruFocus
Medtronic (MDT) Sees Price Target Reduced by Baird | MDT Stock News - GuruFocus
Medtronic to split diabetes business into separate entity, targets IPO - Medical Device Network
Needham Reiterates 'Hold' Rating on Medtronic (MDT) | MDT Stock News - GuruFocus
Medtronic: Fiscal Q4 Earnings Snapshot - New Haven Register
Baird Adjusts Price Target on Medtronic to $92 From $94, Maintains Neutral Rating - marketscreener.com
Medtronic Plc Azioni (MDT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.52%
0.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):